US2007178559A1PendingUtilityA1
Platelet promoting protein and the usage thereof
Est. expirySep 30, 2024(expired)· nominal 20-yr term from priority
A61K 38/00C07K 2319/21A61P 7/00C07K 14/52A61P 7/04
48
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention discloses a protein that has strong affinity to thrombopoietin receptor (C-MPL) and the nucleotide sequences of the protein. The protein is capable of increasing the numbers of platelets and enhancing the blood clotting in vivo and is named as platelet promoting protein (PPP). The protein and its nucleotide sequences can be used for the treatment of blood diseases including thrombocytopenia.
Claims
exact text as granted — not AI-modified1 . An isolated human-derived protein, having an amino acid sequence of:
MGGEQEEERF DGMLLAMAQQ HEGGVQELVN TFFSFLRRKT
DFFIGGEEGM AEKLITQTFS HHNQLAQKTR REKRARQEAE
RREKAERAAR LAKEAKSETS GPQIKELTDE EAERLQLEID
QKKDAENHEA QLKNGSLDSP GKQDTEEDEE EDEKDKGKLK
PNLGNGADLP NYRWTQTLSE LDLAVPFCVN FRLKGKDMVV
DIQRRHLRVG LKGQPAIIDG ELYNEVKVEE SSWLIEDGKV
VTVHLEKINK MEWWSRLVSS DPEINTKKIN PENSKLSDLD
SETRSMVEKM MYDQRQKSMG LPTSDEQKKQ EILKKFMDQH
PEMDFSKAKF N;
or a derivative thereof with a function of increasing the numbers of blood platelets.
2 . The isolated protein according to claim 1 , wherein the protein has additional 2-6 histidines at the N-terminus of the protein.
3 . The isolated protein according to claim 1 wherein the amino acid sequence of protein is encoded by the nucleotide sequence of:
atgggcggagagcaggaggaggagcggttcgacggcatgttgctggccat
ggctcagcagcacgagggcggcgtgcaggagcttgtgaacaccttcttca
gcttccttcgacgcaaaacagactttttcattggaggagaagaagggatg
gcagagaagcttatcacacagactttcagccaccacaatcagctggcaca
gaagacccggcgggagaagagagcccggcaggaggccgagcggcgggaga
aggcggagcgggcggccagactggccaaggaagccaagtcagagacctca
gggccccagatcaaggagctaactgatgaagaggcagagaggctgcagct
agagattgaccagaaaaaggatgcagagaatcatgaggcccagctcaaga
acggcagccttgactccccagggaagcaggatactgaggaagatgaggag
gaagatgagaaggacaaaggaaaactgaagcccaacctaggcaacggggc
agacctgcccaattaccgctggacccagaccctgtcggagctggacctgg
cggtccctttctgtgtgaacttccggctgaaagggaaggacatggtggtg
gacatccagcggcggcacctccgggtggggctcaaggggcagccagcgat
cattgatggggagctctacaatgaagtgaaggtggaggagagctcgtggc
tcattgaggacggcaaggtggtgactgtgcatctggagaagatcaataag
atggagtggtggagccgcttggtgtccagtgaccctgagatcaacaccaa
gaagattaaccctgagaattccaagctgtcagacctggacagtgagactc
gcagcatggtggaaaagatgatgtatgaccagcgacagaagtccatgggg
ctgccaacttcagacgaacagaagaaacaggagattctgaagaagttcat
ggatcaacatccggagatggatttttccaaggctaaattcaac.
4 . A plasmid, comprising a nucleotide sequence for encoding the amino acid sequence of the protein according to claim 1 .
5 . The plasmid according to claim 4 , wherein the plasmid is the expression vector PET-PPP.
6 . A method of making a pharmaceutical composition comprising incorporating a protein according to claim 1 in medicament for treatment of thrombocytopenia or hemorrhage.
7 . The method according to claim 6 , wherein the medicament is in a form of injections, powders, tablets, capsules, solutions, suspensions, or emulsions.
8 . The method according to claim 6 , wherein the medicament is in a form for oral administration or in a form administration via subcutaneous injection, intravenous injection or intramuscular injection.
9 . A pharmaceutical composition, comprising the protein according to claim 1 or a derivative thereof with a function of increasing the numbers of platelets, and at least one pharmaceutically acceptable excipient.
10 . A method for treating a patient suffering from thrombocytopenia, comprising the step of administrating to the patient an effective amount of the protein according to claim 1 or having an effective amount of the protein according to claim 1 expressed in the patient.Join the waitlist — get patent alerts
Track US2007178559A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.